Halving the time a patient with high-risk prostate cancer (PCa) is on androgen deprivation therapy (ADT) is safe and does not compromise outcomes, researchers concluded. Read the article, which includes a short video.
ADT Duration for Prostate Cancer Can Be Cut in Half Read More »
Men with low-risk prostate cancer who previously had to choose between aggressive treatment, with the potential for significant side effects, and active surveillance, with the risk of disease progression, may have a new option. Focal laser ablation uses precisely targeted heat, delivered through a small insertion and guided into the prostate by magnetic resonance imaging, to burn away cancerous cells in the prostate. Read the article.
Focal Therapy Offers Middle Ground for Some Prostate Cancer Patients Read More »
January 2013 Scotiabank Awateness Night Dr.Laurence Klotz, MD, FRCSC Professor, Department of Surgery, University of Toronto Chief, Division of Urology, Sunnybrook Health Sciences Centre Chair, Canadian Uro-Oncology Group and NCIC GU Site Group Editor in Chief (founding), Canadian Journal of Urology Chair, Global GU Oncology Group For localized prostate cancer, the choice of treatment is becoming less straightforward as preferences shift to less aggressive, less intrusive, and increasingly sophisticated approaches. This presentation provides guidance and insight…with focus on active surveillance, focal therapy, MRI imaging, and recent developments in surgery. CLICK ON THE ARROW TO START THE VIDEO “Navigating treatment
VIDEO: Dr. Laurence Klotz, “Navigating treatment options for localized prostate cancer” Read More »
Evan Y. Yu, MD describes his clinical approach to the treatment patients with bone metastases secondary to prostate cancer. View this video.
Optimizing Therapeutic Strategies Targeting Bone: Prostate Cancer Read More »
Abstract Over the past decade, the treatment landscape in metastatic castration-resistant prostate cancer (CRPC) has markedly changed, with the introduction of three new chemotherapeutic agents. The mechanism of CRPC is not fully understood, but it may result from multiple pathways, including a loss or androgen receptor (AR) specificity and increased downstream signalling activity that provide multiple targets for therapeutic agents. For some years, docetaxel was the mainstay of treatment in CRPC, but recently, cabazitaxel (a microtubule inhibitor), sipuleucel-T (a cancer vaccine), and abiraterone acetate (a CYP17 inhibitor) were approved for CRPC treatment. In Phase III clinical trials, these agents have
November 2012 Awareness Night “Radiation Therapy for Prostate Cancer in 2012 and beyond.” Dr. Padrick Warde, MD, MCChB BAO, FRCPC Professor, Department of Radiation Oncology, University of Toronto Staff Radiation Oncologist, The Princess Margaret Cancer Centre/University Health Network Associate Director, Radiation Medicine Program, The Princess Margaret Cancer Centre CLICK ON THE ARROW TO START THE VIDEO Complete Presentation “Radiation Therapy for Prostate Cancer in 2012 and beyond.” High Definition 49inutes Click here to return to top. Click here to return to our main “Videos” page.
VIDEO: Dr. Padrick Warde, “Radiation Therapy for Prostate Cancer in 2012 and beyond.” Read More »
Below is a partial list of possible treatments for prostate cancer. Not all of them are covered by provincial health insurance, or are even available in Canada. Some of them are only available as clinical trials, here or abroad. Discuss with your doctor which treatments may be appropriate for you. The earlier prostate cancer is detected, the more possible treatments are available to you (and the more complex your treatment decision becomes). Articles on some of these treatments can be found under Treatments in the light blue toolbar above. Primary Treatments: These are possible first treatments: – Active surveillance (A
List of Treatments Read More »
A medical researcher with the University of Alberta and his team just published their findings about their work on developing ‘homing beacon drugs’ that kill only cancer cells, not healthy ones, thanks to nano-technology. Read More.
‘Homing Beacon Drugs’ to Target Cancer Cells Read More »
Patients with organ-confined prostate cancer may have a new treatment option using high doses of focused stereotactic body radiotherapy (SBRT) instead of traditional lengthy radiotherapy courses or surgery, according to new data presented at the American Society for Radiation Oncology annual meeting. Read More.
One-Week Radiotherapy Course An Option for Localized PCa Read More »
Men with metastatic castration-resistant prostate cancer (CRPC) lived significantly longer when treated with a bone-targeted, alpha-emitting agent, a randomized trial showed. Read More.
Radium-223 Extends Survival in CRPC Read More »